Connect← Return to Anyone diagnosed with Aggressive Variant Prostate Carcinoma (AVPC)?
Discussion
Anyone diagnosed with Aggressive Variant Prostate Carcinoma (AVPC)?
Prostate Cancer | Last Active: Oct 4 2:26pm | Replies (21)Comment receiving replies
It appears that you have neuroendocrine Prostate cancer. Have they done an FDG PET scan to verify that it can be found? A regular PSMA PET scan doesn’t really detect that kind of prostate cancer since it doesn’t have PSMA.
That type of prostate cancer is not able to be treated by normal means. It doesn’t produce PSA, Did you have a very low PSA? It could be you have a mix of regular prostate cancer that can be treated and neuroendocrine which really requires Chemo with carboplatin.
Do a search on the web for DLL3 clinical trials. Those are trials to try to find something to treat neuroendocrine prostate cancer. I Found that the clinicaltrials.gov website doesn’t really have anything. But a web search can find a few different trials going on. I did it for someone a couple of days ago on another forum.
The two guys I know that had that type of prostate cancer passed within a year. One of them tried to get into one of the trials, but he was too sick to join it.
Replies to "It appears that you have neuroendocrine Prostate cancer. Have they done an FDG PET scan to..."
Connect
@jeffmarc - Geez Jeff. Aren't you a breath of fresh air today. At least oncology listed my
prognosis at 1-2 years. 🤣🤣🤣
Just kidding, of course.
Here's the jist of the conversation. My choice,
1) Docetaxel - Clinical improvement demonstrated in approximately 50% of patients. Side effects may be severe but are typically more manageable.
2) Carboplatin / Cabazitaxel w/ prednisone - Has demonstrated increased effectiveness but side effects are typically more pronounced and more difficult to manage.
3) Start with Taxotere and evaluate after cycle 3. Effectiveness should be measurable at that point and if negative results, decide whether to move on to option 2.
I chose option 3. Riding that fine line between quality and quantity.
Since PSA keeps bouncing from low to elevated, suspicion is that there are variable cancer types. ADT demonstrated pronounced lymph system effectiveness; however, rapidly advancing bone metastasis, coupled with TP53 and ASXL1 mutations indicate a AVPC component.